Novavax

Sanofi inks US$1.2 billion vaccine licensing deal with Novavax

Novavax wants to bring down its expenses below US$750 million this year.

Novavax to cut 12% of its global workforce

The layoffs, part of Novavax’s ongoing cost-reduction measures, would translate to about 498 jobs out of the 1,992 full-time employees it had as of Feb 21 according to the company’s latest regulatory filings.

Novavax lays off 25% of workforce, releases 2023 outlook

The capital raise and supply agreement changes are the latest in a recent string of obstacles for the company.

Novavax tumbles on cut to UK Covid vaccine-supply deal, capital raising

A panel of experts convened by the US drug regulator was meeting on Tuesday (Jun 7) to consider authorizing the Novavax Covid-19 shot, a late runner in the fight against the virus that could nonetheless play a role in overcoming vaccine hesitancy.

FDA experts weigh authorising Novavax Covid-19 vaccine in US

Novavax slumped 20 per cent on Friday (Jun 4) after US regulators raised concerns over the biotech’s much-anticipated Covid-19 vaccine. 

Novavax plunges on ‘harsh’ FDA review ahead of Tuesday panel

JAPAN'S Takeda Pharmaceutical said on Wednesday (May 11) its 12-month operating profit slid 9.5 per cent, although the country's largest drugmaker forecast a rebound for the current year.

Japan's Takeda forecasts rebound despite full-year profit drop